In_vivo_detection_of_somatostatin_receptors_in_patients_with_functionless_pituitary_adenomas_by_means_of_a_radioiodinated_analog_of_somatostatin_(123ISDZ_204-090)._The_recent_availability_of_a_Tyr3-substituted_octreotide_(SDZ_204-090)_for_radioiodination_has_allowed_somatostatin_(SRIH)_receptor_binding_to_be_studied_in_vivo,_and_receptor-positive_tumors_of_different_origins_to_be_visualized_with_a_gamma-camera._This_prompted_us_to_investigate_whether_this_compound_could_be_used_for_external_imaging_of_functionless_pituitary_adenomas_displaying_SRIH_receptors._Eight_patients_with_functionless_pituitary_adenomas,_three_patients_with_acromegaly,_and_three_with_macroprolactinoma_were_injected_iv_with_123I-labeled_Tyr3-octreotide_and_then_scanned_with_a_gamma-camera._Positive_scans_were_obtained_in_the_three_acromegalics_and_in_two_of_the_eight_patients_with_functionless_pituitary_tumors._The_patients_with_macroprolactinoma_had_negative_scans._The_diagnosis_of_functionless_pituitary_adenomas_was_confirmed_by_light_and_electron_microscopic_examination_as_well_as_immunocytochemical_studies._In_vitro_binding_of_125ITyr11-SRIH_to_cell_membranes_was_evaluated_in_four_functionless_and_three_GH-secreting_adenomas_removed_from_seven_of_the_patients._All_of_the_GH-secreting_as_well_as_one_of_the_four_functionless_adenomas_had_high_affinity_SRIH-binding_sites,_without_differences_in_number_or_affinity,_whereas_SRIH-binding_sites_were_not_detected_in_the_others._Positive_scans_were_observed_only_in_patients_bearing_tumors_with_high_affinity_SRIH-binding_sites._In_conclusion,_123ITyr3-octreotide_appears_to_be_a_promising_tool_for_singling_out,_in_vivo,_patients_with_functionless_pituitary_tumors_displaying_SRIH_receptors_who_might_potentially_benefit_from_octreotide_treatment.